Valproic Acid — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	10-20 mg/kg	q8h	Duration: Long-term (titrate to effect) Notes: Due to short half-life, frequent dosing is required. Monitor plasma levels; therapeutic range is 50-100 µg/mL, but levels are often low due to rapid metabolism.
Cat	PO	10-20 mg/kg	q8-12h	Duration: Long-term (titrate to effect) Notes: Cats may have slightly longer half-life than dogs, but still requires frequent dosing. Monitor for hepatotoxicity.
Horse	PO	Not established	Not established	Duration: Not established Notes: Limited data; not recommended for routine use.

Clinical Indications & Species Uses

General Indications

Adjunctive treatment of seizures (especially in dogs and cats)

Dog (Canine)

Adjunctive therapy for refractory epilepsy
Seizure control when other anticonvulsants are ineffective

Cat (Feline)

Adjunctive therapy for refractory epilepsy
Seizure control when other anticonvulsants are ineffective

Pharmacology & Mechanism of Action

Drug Class: Anticonvulsant | Pharmacological Group: Fatty acid derivative

Mechanism of Action: Valproic acid increases the concentration of gamma-aminobutyric acid (GABA) in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, thereby enhancing GABAergic inhibitory neurotransmission. It also blocks voltage-gated sodium channels and T-type calcium channels, reducing neuronal excitability and stabilizing the neuronal membrane.

Pharmacodynamics: Valproic acid produces anticonvulsant effects by elevating brain GABA levels, which suppresses abnormal neuronal discharges. It also modulates dopaminergic and serotonergic transmission, contributing to its mood-stabilizing properties. In veterinary patients, it is used primarily for seizure control, though its efficacy is variable and often limited by pharmacokinetic issues.

⚡ Pharmacokinetics Summary

Absorption: Valproic acid is rapidly and almost completely absorbed after oral administration in most species. Peak plasma concentrations occur within 1-2 hours in dogs and cats. Food may delay absorption but does not significantly reduce the extent.

Distribution: Valproic acid is widely distributed throughout the body, with a volume of distribution of approximately 0.2-0.4 L/kg in dogs. It crosses the blood-brain barrier and placenta, and is distributed into breast milk. Protein binding is concentration-dependent, ranging from 80-90% at therapeutic concentrations.

Metabolism: Valproic acid is extensively metabolized in the liver via glucuronidation, beta-oxidation, and cytochrome P450 (CYP) enzymes. Major metabolites include valproic acid glucuronide and various oxidative products. In dogs, metabolism is rapid, leading to short half-life and low plasma concentrations.

Excretion: Valproic acid and its metabolites are primarily excreted in the urine, with less than 5% excreted unchanged. Biliary excretion also occurs. In dogs, the elimination half-life is very short (approximately 1-2 hours), which limits its clinical utility.

Half-Life: Dog: 1-2 hours; Cat: 2-4 hours; Horse: 1-2 hours; Humans: 10-16 hours

Bioavailability: Oral bioavailability is nearly 100% in most species, but due to rapid metabolism, systemic exposure is low in dogs.

Protein Binding: 80-90% (concentration-dependent)

Available Formulations & Strengths

Oral Tablet 125 mg, 250 mg, 500 mg (PO)

Oral Capsule (delayed-release) 125 mg, 250 mg, 500 mg (PO)

Oral Solution 250 mg/5 mL (PO)

Injectable Solution (IV) 100 mg/mL (IV)

Contraindications & Clinical Warnings

Contraindications:

Known hypersensitivity to valproic acid
Severe hepatic disease
Pregnancy (especially first trimester) unless benefits outweigh risks
Lactation (unless benefits outweigh risks)
Use with caution in patients with mitochondrial disorders

Warnings & Clinical Precautions:

Hepatotoxicity can occur, especially in young animals and those with pre-existing liver disease.
Pancreatitis has been reported in humans and may occur in animals.
May cause thrombocytopenia and platelet dysfunction.
Use with caution in patients with bleeding disorders.
Abrupt withdrawal may precipitate seizures; taper dose gradually.
Monitor liver enzymes, platelet counts, and serum valproic acid levels periodically.
In dogs, due to rapid metabolism, therapeutic levels are difficult to maintain; consider alternative anticonvulsants.

Adverse Effects & Reactions

Common:

Sedation
Ataxia
Vomiting
Diarrhea
Increased appetite
Tremors

Serious / Severe:

Hepatotoxicity
Pancreatitis
Thrombocytopenia
Coagulopathy
Hyperammonemia
Encephalopathy

Rare:

Bone marrow suppression
Stevens-Johnson syndrome
Alopecia
Polycystic ovary syndrome (in humans)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Phenobarbital	Phenobarbital induces hepatic enzymes, increasing valproic acid metabolism and reducing its efficacy.	Moderate
Phenytoin	Valproic acid may displace phenytoin from protein binding sites, increasing free phenytoin levels and toxicity.	Moderate
Carbamazepine	Valproic acid may inhibit carbamazepine metabolism, increasing carbamazepine levels and toxicity.	Moderate
Aspirin	Aspirin may displace valproic acid from protein binding, increasing free valproic acid levels and risk of toxicity.	Mild
Warfarin	Valproic acid may potentiate the anticoagulant effect of warfarin by inhibiting its metabolism.	Moderate
Clonazepam	Valproic acid may increase clonazepam levels, leading to increased sedation.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Severe sedation
Coma
Respiratory depression
Hypotension
Metabolic acidosis
Hypernatremia
Hepatic failure

Emergency Treatment Protocol: Treatment is primarily supportive. Induce emesis if recent ingestion and patient is conscious. Administer activated charcoal to reduce absorption. Provide intravenous fluids and electrolyte correction. Monitor vital signs, liver function, and coagulation parameters. In severe cases, hemodialysis may be considered. There is no specific antidote.

Food Animal Withdrawal Times

Not approved for use in food animals; withdrawal times not established. Use in food animals is prohibited or requires extended withdrawal periods under extra-label regulations.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25°C) in a tightly closed container.

Handling & Special Conditions: Protect from moisture. Keep out of reach of children and animals.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use.

Extra-Label (Off-Label) Use: In the US, extra-label use in animals is permitted under AMDUCA, but only by or on the order of a licensed veterinarian within a valid VCPR. Not approved for veterinary use; use in food animals requires extended withdrawal periods and is generally discouraged.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Valproic acid is rarely used in veterinary medicine due to its short half-life in dogs and cats, which necessitates frequent dosing and often results in subtherapeutic plasma concentrations. It may be considered as an adjunctive therapy for refractory seizures when other anticonvulsants (e.g., phenobarbital, potassium bromide) have failed. However, its use is limited by the need for close monitoring of liver enzymes, platelet counts, and serum drug levels. Alternative anticonvulsants such as levetiracetam or zonisamide are often preferred due to better pharmacokinetic profiles and safety. If valproic acid is used, it should be administered at the lowest effective dose and titrated gradually. Abrupt discontinuation should be avoided to prevent rebound seizures. Due to the risk of hepatotoxicity, periodic liver function tests are essential. In cats, caution is advised due to increased susceptibility to hepatic injury.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)